Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qizhu Yuling Prescription for Postoperative Esophageal Cancer
NCT05626309Unknown
- Start
- Oct 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in esophageal cancer comparing Qizhu Yuling Prescription with Placebo Comparator (2 arms). Primary endpoint: 1-year disease-free survival rate. Status: unknown.
02
Drugs
Qizhu Yuling Prescription
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT05626309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626309.